Persistent activity of doramectin injectable formulation against experimental challenge with Haemonchus placei in cattle.
Two studies were conducted in North America to evaluate the persistent activity of doramectin injectable formulation against experimental challenge with Haemonchus placei. In both studies, calves were randomly assigned to 1 of 4 treatment groups (n = 10 per group) or a larval viability group (n = 2). Calves were treated subcutaneously in the lateral midline of the neck with saline (1 ml/50 kg) on Day 0, or with doramectin (200 mg/kg = 1 ml/50 kg) on Day 0, 7, or 14. Animals used to assess larval viability did not receive any treatment. Beginning on Day 14 and continuing through Day 28, each of the 40 treated calves were given approximately 300 infective larvae of H. placei per os. The two larval viability animals received approximately 10,000 larvae as a single dose on Day 28. Approximately two weeks later, all animals were slaughtered and the abomasum from each calf processed for nematode recovery. A 2% aliquot of abomasal contents plus wash was examined for enumeration and identification of nematodes. Geometric mean H. placei counts were calculated from the log (H. placei count +1) and used to estimate percentage reduction. Overall, doramectin was > or =96.9% efficacious in reducing infection with H. placei when challenged daily 14-28 days after treatment.
Ballweber
L R
LR
College of Veterinary Medicine, Mississippi State University, MS 39762, USA. ballweber@cvm.msstate.edu
Siefker
C
C
Engelken
T
T
Walstrom
D J
DJ
Skogerboe
T
T
D000018:Abomasum / Q000469:parasitology; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000592:standards* / Q000627:therapeutic use; D001131:Arkansas; D002417:Cattle; D002418:Cattle Diseases / Q000469:parasitology / Q000517:prevention & control*; D006188:Haemonchiasis / Q000517:prevention & control / Q000662:veterinary*; D006189:Haemonchus / Q000187:drug effects / Q000254:growth & development / Q000302:isolation & purification; D007279:Injections, Subcutaneous / Q000662:veterinary; D007559:Ivermectin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000592:standards / Q000627:therapeutic use; D008297:Male; D008922:Mississippi; D011897:Random Allocation
D000871:Anthelmintics; D007559:Ivermectin; C084101:doramectin